Merck, Plaintiffs Fail To Reach Deal In Fosamax Jaw MDL

Law360, New York (August 15, 2013, 7:24 PM EDT) -- Merck & Co. Inc. and a group of plaintiffs in multidistrict litigation over jaw injuries allegedly caused by the bone drug Fosamax broke off settlement talks on Wednesday, a day after a judge peppered the drugmaker with questions about why it has not yet resolved the litigation.

A mediation session between Merck and attorneys from Levin Papantonio Thomas Mitchell Rafferty & Proctor PA and Ashcraft & Gerel LLP, who were negotiating on behalf of plaintiffs in approximately 370 cases in the litigation, ended in an impasse,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.